Published in J Infect Dis on January 01, 1996
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits. Hum Vaccin (2008) 1.67
Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun (1999) 1.15
Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats. Infect Immun (1997) 1.15
Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model. Infect Immun (1998) 1.12
Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect Immun (1999) 1.12
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun (2002) 1.08
Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent. Infect Immun (1998) 1.03
Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun (2001) 0.95
Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun (1998) 0.95
Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis (2013) 0.92
Lectin site interaction with capsular polysaccharide mediates nonimmune phagocytosis of type III group B streptococci. Infect Immun (2000) 0.88
Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Hum Vaccin (2008) 0.84
Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching. Proc Natl Acad Sci U S A (2008) 0.84
Isolation of highly active monoclonal antibodies against multiresistant gram-positive bacteria. PLoS One (2015) 0.79
Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity. Clin Vaccine Immunol (2006) 0.79
The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways. J Immunol (2015) 0.79
Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation. Vaccine (2009) 0.77
Measurement of human antibodies to type III group B Streptococcus. Infect Immun (1999) 0.76
Immune Responses to Invasive Group B Streptococcal Disease in Adults. Emerg Infect Dis (2016) 0.75
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Transmission of group B streptococci among parturient women and their neonates. J Pediatr (1973) 6.86
Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr (1973) 6.29
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA (1998) 4.94
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol (1973) 4.49
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Selective broth medium for isolation of group B streptococci. Appl Microbiol (1973) 4.42
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
Group B streptococcal infections in infants. The importance of the various serotypes. JAMA (1974) 3.71
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Typing of group B streptococci: comparison of pulsed-field gel electrophoresis and conventional electrophoresis. J Clin Microbiol (1993) 3.52
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Continuous and discontinuous protein antigenic determinants. Nature (1986) 3.26
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen. Rev Infect Dis (1983) 3.23
The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J Infect Dis (1976) 3.20
Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med (1988) 3.14
Active oxygen in plant pathogenesis. Annu Rev Phytopathol (1995) 3.02
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest (1990) 2.96
Bacteroides fragilis subspecies in clinical isolates. Ann Intern Med (1977) 2.95
Structural features of polysaccharides that induce intra-abdominal abscesses. Science (1993) 2.86
Molecular cloning of a Pseudomonas syringae pv. syringae gene cluster that enables Pseudomonas fluorescens to elicit the hypersensitive response in tobacco plants. J Bacteriol (1988) 2.84
Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature (2001) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci U S A (1992) 2.65
Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med (1976) 2.55
Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis (1999) 2.50
Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J Infect Dis (1973) 2.47
Involvement of plasma membrane calcium influx in bacterial induction of the k/h and hypersensitive responses in tobacco. Plant Physiol (1990) 2.46
Characterization of gonococcal antigens responsible for induction of bactericidal antibody in disseminated infection. J Clin Invest (1977) 2.46
Neonatal sepsis caused by a new group B streptococcal serotype. J Pediatr (1993) 2.45
Chemical and biological characterization of the lipopolysaccharide of Bacteroides fragilis subspecies fragilis. J Infect Dis (1976) 2.45
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Immunochemical characterization of the outer membrane complex of Bacteroides fragilis subspecies fragilis. J Infect Dis (1975) 2.39
Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun (1976) 2.38
Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem (1987) 2.35
Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A (1996) 2.34
Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem (2001) 2.30
In whose best interest? Breaching the academic-industrial wall. N Engl J Med (2000) 2.28
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1993) 2.26
Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest (1977) 2.23
Location of 'continuous' antigenic determinants in the protruding regions of proteins. EMBO J (1986) 2.22
Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry (1981) 2.17
Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci. Infect Immun (1978) 2.15
Comparison of bacteriological methods for the isolation of group of B Streptococcus from vaginal cultures. J Clin Microbiol (1976) 2.14
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A (1989) 2.13
Changing epidemiology of group B streptococcal colonization. Pediatrics (1999) 2.09
A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect Immun (1991) 2.06
Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med (1979) 2.06
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol (2010) 2.02
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem (1992) 2.00
Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother (1998) 2.00
Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry (1992) 1.98
Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun (1991) 1.97
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infect Immun (1991) 1.95
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
The changing spectrum of group B streptococcal disease. N Engl J Med (1993) 1.94
Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest (1995) 1.91
Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect Immun (1993) 1.90
Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. J Clin Microbiol (1989) 1.87
Surgical treatment of syringomyelia. Favorable results with syringoperitoneal shunting. J Neurosurg (1984) 1.84
Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics (1981) 1.83
Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem (1980) 1.83
Neonatal mouse model of group B streptococcal infection. J Infect Dis (1992) 1.82
Skull base and calvarial deformities: association with intracranial changes in craniofacial syndromes. AJNR Am J Neuroradiol (1996) 1.81
Mouse protection test for group B Streptococcus type III. J Infect Dis (1979) 1.80
Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis (2000) 1.79
Persistent bacteremia due to coagulase-negative staphylococci in low birth weight neonates. Pediatrics (1989) 1.78
Recurrent meningitis and Mondini dysplasia. Arch Otolaryngol Head Neck Surg (1990) 1.77
Vaginal colonization with group B streptococcus: a study in college women. J Infect Dis (1977) 1.76
Group B streptococcal vaccines. Rev Infect Dis (1985) 1.74
Revised classification of posterior fossa cysts and cystlike malformations based on the results of multiplanar MR imaging. AJR Am J Roentgenol (1989) 1.74
Isolation and identification of encapsulated strains of Bacteroides fragilis. J Infect Dis (1977) 1.74
Group B streptococcal infections. Adv Intern Med (1980) 1.72
Antimicrobial susceptibility of group B streptococci isolated from a variety of clinical sources. Antimicrob Agents Chemother (1976) 1.72